| |
|
|
|
CfPA-The Center for Professional Advancement, Amsterdam, The Netherlands
13-15 October 2014
Who Should Attend
This is an in depth course intended for product development scientists and technologists and support groups concerned with the development, designing and processing of tablets and similar oral products.
The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
• Formulation Development
• Quality Assurance
• Research and Development
• Validation
• Regulatory Affairs
• Manufacturing/Production
• Engineering Support
Note: Persons seeking a broader based program may wish to consider an alternative, more generalized course offered by CfPA in this area of technology. Description
The main aim of this 3-day intensive course is to review the science relating to formulation and process selection in the design of tabletted pharmaceutical products. The course begins with a consideration of the final process of making tablets and meeting the challenges of the API and delivering the targeted therapy. Knowing the targets, the ingredients available and the selection criteria for ingredients are reviewed. The impact of the API, the choosen platform and the strategies for choosing the processes to obtain the targeted performance are reviewed. The program concludes with key aspects of designing principles of setting up DOEs and the role of QbD in creating the operating/design space, investigation and eliminate risk. Evaluation, problem solving and regulatory constraints are discussed at each stage.
Formal sessions of the course are supplemented with informal discussion periods between lecturers and course participants and problem-solving sessions are held on both an open and private basis.
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA-The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
Dr. Cecil W. Propst; Director R&D, SPI Pharma, Inc., Grand Haven, MI
Dr. Cecil W. Propst is Director of R&D for SPI Pharma (Grand Haven site), a processor of a variety of specialty ingredients for the food, drug, cosmetic and related industries. He was Director of Quality Assurance and Technical Development at Fleming and Company and President of Manufacturing Chemists. His duties included system design, product and process development, and regulatory affairs. Previously, he served as cGMP Facilities Director for the University of Maryland at Baltimore in connection with the University’s contract with the FDA.
Dr. Propst also served as Director of Technical Development for Stellar Manufacturing, Director of Quality Compliance for SmithKline Beecham, Director of Quality Assurance for Norcliff Thayer (a Revlon Company), Group Leader/Product Development and Manager/ Quality Control for Lewis Howe Company. He consults with TabTech for the chemical, diagnostic, food, engineering and beverage industries.
Dr. John K Tillotson; Global Applications Manager, SPI Pharma, Inc., Grand Haven, MI
Dr. John Tillotson, Global Applications Manager at SPI Pharma, Inc., received his B.S. in Pharmacy from Ferris State University and his Ph.D. in Industrial Pharmacy from the University of Cincinnati.
Dr. Tillotson’s primary areas of interest are quick dissolve tablet technologies, directly compressible modalities and multipleregression analysis. He was involved with the development and optimization of bumetanide sustained release technologies has several quick dissolve systems for nutraceuticals, OTC, and prescription products. Dr. Tillotson has presented at various workshop, invited symposium, and/or poster presentations at national and international meetings. His published papers discuss the use of multiple-response optimization and the benefits of various ODT excipient systems. He is a member of the Rho Chi Pharmaceutical Honor Society and of the American Association of Pharmaceutical Scientists.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
sberg@cfpa.com
|
|
|
|
|
|
|
|
|